Insufficient scRNA-seq data for expression of GPR31 at single-cell level.
Insufficient scRNA-seq data for expression of GPR31 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
spleen | 76% | 6.21 | 184 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 55% | 1.39 | 16 / 29 |
intestine | 29% | 1.99 | 277 / 966 | 1% | 0.01 | 3 / 527 |
breast | 18% | 0.58 | 83 / 459 | 8% | 0.12 | 92 / 1118 |
lung | 25% | 0.85 | 144 / 578 | 1% | 0.01 | 9 / 1155 |
thymus | 20% | 0.73 | 132 / 653 | 4% | 0.07 | 24 / 605 |
peripheral blood | 24% | 1.23 | 221 / 929 | 0% | 0 | 0 / 0 |
kidney | 20% | 0.66 | 18 / 89 | 3% | 0.05 | 28 / 901 |
brain | 15% | 0.45 | 396 / 2642 | 1% | 0.01 | 7 / 705 |
tonsil | 0% | 0 | 0 / 0 | 16% | 0.18 | 7 / 45 |
stomach | 14% | 0.41 | 49 / 359 | 1% | 0.01 | 3 / 286 |
ovary | 6% | 0.15 | 10 / 180 | 9% | 0.16 | 38 / 430 |
skin | 6% | 0.15 | 114 / 1809 | 6% | 0.11 | 29 / 472 |
esophagus | 8% | 0.25 | 119 / 1445 | 0% | 0 | 0 / 183 |
uterus | 7% | 0.21 | 12 / 170 | 1% | 0.01 | 3 / 459 |
pancreas | 8% | 0.18 | 25 / 328 | 0% | 0 | 0 / 178 |
adipose | 7% | 0.22 | 88 / 1204 | 0% | 0 | 0 / 0 |
liver | 6% | 0.15 | 14 / 226 | 1% | 0.01 | 3 / 406 |
prostate | 7% | 0.16 | 16 / 245 | 0% | 0.01 | 2 / 502 |
blood vessel | 6% | 0.18 | 86 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 5% | 0.13 | 14 / 258 | 0% | 0 | 0 / 230 |
bladder | 5% | 0.10 | 1 / 21 | 0% | 0 | 0 / 504 |
heart | 3% | 0.08 | 26 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 0.07 | 20 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002237 | Biological process | response to molecule of bacterial origin |
GO_0050778 | Biological process | positive regulation of immune response |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0002931 | Biological process | response to ischemia |
GO_0006629 | Biological process | lipid metabolic process |
GO_0010447 | Biological process | response to acidic pH |
GO_0005886 | Cellular component | plasma membrane |
GO_0050544 | Molecular function | arachidonic acid binding |
GO_0045125 | Molecular function | bioactive lipid receptor activity |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | GPR31 |
Protein name | 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor (12-(S)-HETE receptor) (12-HETER) (G-protein coupled receptor 31) (GPR31/12-HETER) |
Synonyms | |
Description | FUNCTION: High-affinity receptor for 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12-S-HETE), with much lower affinities for other HETE isomers . 12-S-HETE is a eicosanoid, a 12-lipoxygenase (ALOX12) metabolite of arachidonic acid, involved in many physiologic and pathologic processes . 12-S-HETE-binding leads to activation of ERK1/2 (MAPK3/MAPK1), MEK, and NF-kappa-B pathways leading to cell growth . Plays a crucial role for proliferation, survival and macropinocytosis of KRAS-dependent cancer cells by mediating the translocation of KRAS from the endoplasmic reticulum to the plasma membrane (PM) and its association with the PM . Contributes to enhanced immune responses by inducing dendrite protrusion of small intestinal CX3CR1(+) phagocytes for the uptake of luminal antigens (By similarity). Acts also as a key receptor for 12-(S)-HETE-mediated liver ischemia reperfusion injury . .; FUNCTION: Proton-sensing G protein-coupled receptor. . |
Accessions | O00270 ENST00000366834.2 |